By acknowledging the individuality of each Parkinson’s patient, the device significantly minimises diagnostic time and uncertainty. Credit: R Photography Background / Shutterstock.

QuantalX Neuroscience has introduced the new Delphi-MD device for the early detection and subtyping of Parkinson’s disease.

The device, part of the company’s extensive neurological disease diagnostic portfolio, employs direct electrophysiological imaging technology to provide real-time insights into brain network function.  

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This system can identify specific physiological changes within brain networks, particularly the occipital networks, which manifest during the initial stages of the disease.

It will enable healthcare professionals to pinpoint patients who may experience rapid disease progression. This capability facilitates early intervention and tailored treatment plans.

Furthermore, Delphi-MD’s advanced technology allows for the early and accurate detection of Parkinson’s neurophysiological subtypes by recognising distinct electrophysiological alterations in crucial brain networks.

By acknowledging the individuality of each Parkinson’s patient, the device significantly minimises diagnostic time and uncertainty.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This innovation is poised to transform clinical practice by refining treatment selection and disease monitoring.

It offers clinicians real-time insights for personalised therapeutic strategies, thereby improving patient care.

NINDS, NIH Human Motor Control Section former chief professor Mark Hallett said: “Delphi-MD represents a leap forward in our ability to confirm the diagnosis of Parkinson’s disease at an earlier stage. The precision and clarity it provides in detecting subtle brain network changes could revolutionise how we approach treatment and patient care.”

With Delphi-MD’s verified ability to detect network dysfunctions associated with Parkinson’s, it is expected to revolutionise the way healthcare systems and pharmaceutical companies approach diagnosis and treatment selection. 

QuantalX leverages the new Direct Neuro-Physiological technology, the Delphi-MD device, to improve patient care and reduce the burden on healthcare systems.